Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Jefferies's Glen Santangelo raised their price target on Healthequity (NASDAQ: HQY) by 3.1% from $130 to $134 on 2025/09/03. The analyst maintained their Strong Buy rating on the stock.

HealthEquity reported its Q2 2026 earnings.

Santangelo said their optimistic view of the name is intact post-print, citing the outstanding results and guidance hike as proof of management's ongoing strong performance, "which is translating into stock-driving profit outperformance."

The analyst said they believe the company's future revenue and profits projections will be propelled by the favorable impact of the One Big Beautiful Bill Act's expansion of HSA eligibility. 

Santangelo noted that the stock more than sufficiently reflects concerns about interest rates.

Earnings Report

For Q2 2026, Healthequity reported:

• EPS of $1.08, which beat the Zacks Consensus Estimate of $0.92 and, by 26%, Q2 2025’s $0.86.
• Revenue of $325.84M, which beat the Zacks Consensus Estimate by 2.20% and, by 9%, Q2 2025’s $299.93M.

For FY 2026, management guided:

• EPS of $3.74 to $3.91.
• Revenue of $1.29B to $1.31B.

President & CEO Scott Cutler commented: "The HealthEquity team delivered continued momentum during our Q2 with strong 9% revenue growth, record gross margin of 71% and record adjusted EBITDA of $151M.

"We believe our outlook is even brighter with our national lawmakers providing the largest legislative expansion of HSAs since 2006, as more American families seek access to the financial security and tax benefits that they provide. 

“Through our proprietary technologies and platforms, Team Purple continues to empower a growing number of savvy healthcare consumers with tools and resources that drive better member outcomes."